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More than 130 years after the discovery of
Mycobacterium tuberculosis, tuberculosis
remains a matter of life or death for mil-
lions. In 2013, 9.0 million people world-
wide developed the disease and 1.5
million died [1]. The growing problem
of multidrug-resistant (MDR) tuberculo-
sis has ampliﬁed the toll of this epidemic.
An estimated 480 000 new cases of MDR
tuberculosis occur annually and, of these,
an estimated 9.0% also have extensively
drug-resistant (XDR) tuberculosis [1].
The global tuberculosis control strat-
egy aims to achieve rapid diagnosis and
effective treatment of tuberculosis, result-
ing in high cure rates and prevention of
onward disease transmission [2]. It is rec-
ommended that standardized multidrug
treatment regimens are prescribed empi-
rically until the results of drug susceptibility
testing (DST) are available [3]. However,
the stark reality is that <10% of new
tuberculosis cases worldwide had DST
done in 2013, reﬂecting the critical lack
of laboratory capacity [1]. More than
half of the estimated global burden of
MDR tuberculosis cases each year is sim-
ply not diagnosed. Blind use of tuberculo-
sis treatment regimens uninformed by
DST is undoubtedly a key ampliﬁer of
drug resistance.
In the absence of DST results, moni-
toring patients’ response to treatment is
especially important. The World Health
Organization (WHO) recommends that
for patients with pulmonary tuberculosis,
sputum smear microscopy for acid-fast
bacilli is repeated at the end of the inten-
sive phase of treatment [3]. This, howev-
er, is a poor marker of disease activity.
Tuberculosis and other mycobacterial in-
fections such as leprosy are characterized
by the persistence of nonviable acid-fast
bacilli at the site of disease and in clinical
samples, regardless of effective treatment
[4–6]. Thus, WHO-recommended ﬁrst-
line diagnostic tests for tuberculosis
such as sputum smear microscopy and
the Xpert MTB/RIF assay, which detects
mycobacterial DNA, may remain persis-
tently positive and therefore fail to pro-
vide a useful index of disease activity or
treatment response [4–6].
Microbiological assessment of the re-
sponse to tuberculosis treatment requires
assays of the viability of M. tuberculosis
bacilli in clinical samples. As bacterial vi-
ability is conventionally deﬁned by the
loss of the capacity to divide and form
progeny [7], culture is regarded as the ref-
erence standard method to determine vi-
ability. However, mycobacterial culture
requires extended incubation, sophisti-
cated laboratory infrastructure, and high-
ly trained staff. As a result, culture is often
not rapid enough to inform clinical deci-
sion making and is simply not available
in many parts of the world. Various sur-
rogate markers of viability have therefore
been used. Viability polymerase chain re-
action (PCR) involves use of an agent
such as propidium monoazide, which is
able to penetrate dead (but not live) bac-
teria, bind to DNA, and interfere with
PCR ampliﬁcation. Alternatively, reverse
transcription PCR can be used to detect
short-lived messenger RNA [8] or pre–
ribosomal RNA [9], which is synthesized
during brief speciﬁc nutritional sti-
mulation in vitro. The ability of bacterio-
phages to enter and multiply within live
M. tuberculosis has been exploited to de-
termine viability in DST [10]. Important-
ly, none of these are direct markers of
viability, and their kinetics may differ from
that of bacterial culture. For example,
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viability may be rapidly reduced by ultra-
violet damage or pasteurization, but cells
remain intact and impermeable to propi-
dium iodide or monoazide [7].
In this issue of Clinical Infectious Diseas-
es, Datta and colleagues report a clinical
evaluation of another viability assay
among patients with tuberculosis treated
in Peru [11]. This assay does not require
sophisticated laboratory infrastructure,
and it provides an assessment of mycobac-
terial viability based on the enzymatic ac-
tivity of live cells. Esterase activity was
measured with a simple staining method
using the fatty acid ester ﬂuorescein diace-
tate. Nonpolar, nonﬂuorescent ﬂuorescein
diacetate enters live bacilli where it is enzy-
matically hydrolyzed by acetylesterase to
polar, ﬂuorescent ﬂuorescein, which rapid-
ly accumulates in the cytoplasm. When
viewed under LED (light-emitting diode)
ﬂuorescence microscopy, live cells ﬂuoresce
green. Dead bacilli lack functional acetyles-
terase and so do not ﬂuoresce. The latter
can be counterstained using ethidium bro-
mide, which readily enters dead cells and
intercalates within DNA molecules, where-
as functional cell membranes of live bacilli
are able to exclude ethidium bromide.
The ﬂuorescein diacetate viability assay
was described >30 years ago as a means of
assessing the viability of leprosy bacilli,
nontuberculous mycobacteria, andM. tu-
berculosis [12, 13]. Field studies have pre-
viously evaluated this assay against
culture as a means of detecting tuberculo-
sis treatment failure, with variable accura-
cy being reported [14–17]. Challenges
encountered have included limited spe-
ciﬁcity due to background ﬂuorescence,
interfering host tissue debris, and limited
sensitivity due to rapid fading of ﬂuores-
cence [18]. In addition to these few
reports where ﬂuorescein diacetate stain-
ing was used as a viability assay directly
on clinical samples, the technique has
also been applied using a rapid ﬂow cyto-
metric read-out when performing DST
on clinical culture isolates [19, 20].
In their study, Datta and colleagues
studied 35 patients with newly diagnosed
smear-positive pulmonary tuberculosis in
Peru, among whom most (n = 31) had
non-MDR tuberculosis and the remainder
(n = 4) had MDR tuberculosis [11].
Treatment response during the ﬁrst 9
days of ﬁrst-line therapy was assessed by
analyzing sputum samples obtained on
days 0, 3, 6, and 9 of therapy. For each pa-
tient, the results of ﬂuorescein diacetate
viability microscopy were directly com-
pared with those of acid-fast microscopy
and with quantitative culture. Whereas
the results of acid-fast microscopy altered
little during early treatment, a strong
relationship was observed between reduc-
tions in viability microscopy and reduc-
tions in quantitative cultures. Whereas
the viability and quantitative culture re-
sults approximately halved with each
day of treatment in patients with non-
MDR tuberculosis, these both remained
largely unchanged during treatment of
those with MDR tuberculosis. The authors
suggest that viability microscopy might
therefore be used as an early indicator of
poor treatment response and thereby per-
mit early identiﬁcation of drug-resistant
disease. They suggest that viability micros-
copy may be an appropriate-technology
test for use in laboratories in resource-
limited settings for this purpose.
The relationship between viability mi-
croscopy and quantitative culture dem-
onstrated by Datta and colleagues is
strong and plausible. This is the ﬁrst
study to rigorously assess this prospec-
tively over time during early treatment.
However, whether this simple assay
would be feasible to implement and use-
ful in a programmatic setting remains to
be demonstrated. This evaluation repre-
sents an important proof-of-concept
study, but was limited substantially by
the small number of MDR tuberculosis
cases. Larger studies are needed to estab-
lish the positive and negative predictive
values of viability microscopy for MDR
tuberculosis.
A number of features of the assay also
suggest that it may have limited applica-
tion in tuberculosis programs. The test is
only useful to assess patients with sputum
smear–positive pulmonary disease. Be-
cause patient assessment with this assay
in this study involved comparison of
data from samples obtained at >1 time-
point during early treatment, this would
be challenging to implement program-
matically in resource-limited settings.
The predictive value of assay results ob-
tained at a single cross-sectional time-
point needs to be assessed, as others
have done [17]. Although the assay does
not require sophisticated laboratory in-
frastructure or equipment, the required
person-time of a laboratory technologist
is not an insigniﬁcant cost.
A fundamental limitation to this ap-
proach is that although viability micros-
copy may provide early evidence of
nonresponse to tuberculosis treatment,
it does not identify the underlying
cause. Nonresponse may be due to a vari-
ety of reasons, including drug resistance,
treatment nonadherence, drug malab-
sorption, and counterfeit drug supplies.
Investigation of treatment nonresponse
in a patient inevitably requires knowledge
of DST results. Arguably, scarce laborato-
ry resources should be prioritized toward
establishment of capacity for DST. It is
completely unacceptable that in 2013,
<10% of the world’s tuberculosis cases
had DST performed [1]. The advent of
rapid molecular assays, such as the
Xpert MTB/RIF assay, that are able to de-
tect key drug resistance mutations in the
initial diagnostic sample now permit ap-
propriate regimen choices to be made at
the start of treatment [21]. The develop-
ment and implementation of such assays
is an important step forward.
Despite skepticism regarding the sug-
gestion that ﬂuorescein diacetate viabi-
lity microscopy might be widely employed
in tuberculosis programs in resource-
limited settings as a means of early detec-
tion of drug-resistant tuberculosis, the data
presented by Datta and colleagues indi-
cate that this simple assay does merit fur-
ther evaluation. There are a number of
additional applications for use in both
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resource-limited and industrialized set-
tings that would potentially be of value.
The relationship between viability mi-
croscopy and risk of tuberculosis trans-
mission should be explored. Could this
assay be used to deﬁne when patients re-
ceiving treatment for tuberculosis or
MDR tuberculosis are of low infectious
risk and no longer require isolation? Es-
tablishment of patients with MDR tuber-
culosis and XDR tuberculosis on effective
treatment regimens is challenging. Could
ﬂuorescein diacetate viability microscopy
be used to assess regimen efﬁcacy in such
patients, and could regimens be con-
structed and modiﬁed according to serial
assessments of viability microscopy? Sim-
ilarly, could the assay be used as marker of
drug or regimen efﬁcacy in early bacterici-
dal activity studies of new antituberculosis
drugs? Further evaluation and develop-
ment are warranted. This old assay of my-
cobacterial viability may have life in it yet.
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